围手术期免疫疗法在局限性肾细胞癌中的作用。
Role of perioperative immunotherapy in localized renal cell carcinoma.
作者信息
Kaur Jasmeet, Patil Goutham, Geynisman Daniel M, Ghatalia Pooja
机构信息
Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Trinity Health Oakland Hospital, Pontiac, MI, USA.
出版信息
Ther Adv Med Oncol. 2023 Jul 29;15:17588359231181497. doi: 10.1177/17588359231181497. eCollection 2023.
Abstract
Immunotherapy has proven effective in metastatic renal cell carcinoma (RCC). The current standard of treatment in localized RCC is partial or complete nephrectomy. However, after surgery, there is a high recurrence rate and survival rates ranging from 53% to 85% depending on the stage of disease at presentation. Given clinical response to immunotherapies in metastatic RCC, these therapies are being tested as monotherapy and in combination with vascular endothelial growth factor receptor tyrosine kinase inhibitors in the (neo)adjuvant setting. Here we describe the current landscape of these treatments in localized RCC.
摘要
免疫疗法已被证明对转移性肾细胞癌（RCC）有效。局限性RCC目前的治疗标准是部分或全肾切除术。然而，手术后复发率很高，生存率在53%至85%之间，具体取决于疾病初发时的分期。鉴于转移性RCC对免疫疗法的临床反应，这些疗法正在作为单一疗法以及在（新）辅助治疗中与血管内皮生长因子受体酪氨酸激酶抑制剂联合进行测试。在此，我们描述这些治疗方法在局限性RCC中的当前情况。
相似文献
1
Role of perioperative immunotherapy in localized renal cell carcinoma.围手术期免疫疗法在局限性肾细胞癌中的作用。
Ther Adv Med Oncol. 2023 Jul 29;15:17588359231181497. doi: 10.1177/17588359231181497. eCollection 2023.
2
Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future Directions.肾细胞癌的新辅助和辅助免疫治疗方法：利弊与未来方向
Eur Urol Oncol. 2025 Apr;8(2):494-509. doi: 10.1016/j.euo.2024.09.002. Epub 2024 Sep 25.
3
Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade.肾细胞癌的辅助治疗选择 - 靶向转移级联。
Nat Rev Urol. 2023 Mar;20(3):179-193. doi: 10.1038/s41585-022-00666-2. Epub 2022 Nov 11.
4
The Promise of Neoadjuvant and Adjuvant Therapies for Renal Cancer.新辅助和辅助治疗肾癌的前景。
Urol Clin North Am. 2023 May;50(2):285-303. doi: 10.1016/j.ucl.2023.01.011.
5
Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario.肾切除术后局限性肾细胞癌的管理。在不断演变的临床情况下，从风险分层到治疗证据
Cancer Treat Rev. 2023 Apr;115:102528. doi: 10.1016/j.ctrv.2023.102528. Epub 2023 Feb 24.
6
Recent advances in localized RCC: A focus on VEGF and immuno-oncology therapies.局限性肾细胞癌的最新进展：聚焦于血管内皮生长因子和免疫肿瘤学疗法
Urol Oncol. 2018 Jan;36(1):23-30. doi: 10.1016/j.urolonc.2017.09.008. Epub 2017 Oct 16.
7
A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality.根据预期的癌症特异性死亡率，优化当前高风险非转移性肾细胞癌辅助免疫治疗试验中的选择的呼吁。
Clin Genitourin Cancer. 2020 Aug;18(4):314-321.e1. doi: 10.1016/j.clgc.2019.11.010. Epub 2019 Dec 5.
8
Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?肾细胞癌的辅助治疗选择：我们处于什么位置？
Curr Treat Options Oncol. 2019 May 3;20(5):44. doi: 10.1007/s11864-019-0639-0.
9
Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward.转变非转移性肾细胞癌围手术期治疗模式——一条可能的前进道路。
Kidney Cancer. 2017 Jul 26;1(1):31-40. doi: 10.3233/KCA-170010.
10
Adjuvant therapy in renal cell carcinoma.肾细胞癌的辅助治疗。
Cancer. 2019 Sep 1;125(17):2935-2944. doi: 10.1002/cncr.32144. Epub 2019 Jun 21.
引用本文的文献
1
Stereotactic Body Radiotherapy for Renal Cell Carcinoma-A Review of Use in the Primary, Cytoreductive and Oligometastatic Settings.立体定向体部放射治疗在肾癌中的应用——原发性、减瘤性和寡转移性治疗情况综述
Cancers (Basel). 2024 Sep 29;16(19):3334. doi: 10.3390/cancers16193334.
2
Treatment Landscape of Renal Cell Carcinoma.肾细胞癌的治疗全景。
Curr Treat Options Oncol. 2023 Dec;24(12):1889-1916. doi: 10.1007/s11864-023-01161-5. Epub 2023 Dec 28.
3
Mathematical and Machine Learning Models of Renal Cell Carcinoma: A Review.肾细胞癌的数学和机器学习模型：综述
Bioengineering (Basel). 2023 Nov 16;10(11):1320. doi: 10.3390/bioengineering10111320.
本文引用的文献
1
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.接受肾切除术的肾细胞癌患者的围手术期纳武利尤单抗与观察（PROSPER ECOG-ACRIN EA8143）：一项开放标签、随机、III 期研究。
Lancet Oncol. 2024 Aug;25(8):1038-1052. doi: 10.1016/S1470-2045(24)00211-0. Epub 2024 Jun 25.
2
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.纳武利尤单抗联合伊匹单抗辅助治疗肾切除术后局部肾细胞癌（CheckMate 914）：一项双盲、随机、III 期临床试验。
Lancet. 2023 Mar 11;401(10379):821-832. doi: 10.1016/S0140-6736(22)02574-0. Epub 2023 Feb 9.
3
Cancer statistics, 2023.癌症统计数据，2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
4
Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma.帕博利珠单抗作为透明细胞肾细胞癌辅助治疗的相关问题需要澄清。
Lancet Oncol. 2022 Nov;23(11):e489. doi: 10.1016/S1470-2045(22)00629-5.
5
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.阿替利珠单抗辅助治疗与安慰剂用于接受切除术治疗后复发风险增加的肾细胞癌患者（IMmotion010）：一项多中心、随机、双盲、III 期临床试验。
Lancet. 2022 Oct 1;400(10358):1103-1116. doi: 10.1016/S0140-6736(22)01658-0. Epub 2022 Sep 10.
6
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.帕博利珠单抗对比安慰剂用于肾透明细胞癌肾切除术患者的辅助治疗（KEYNOTE-564）：一项多中心、随机、双盲、安慰剂对照、III 期临床试验的 30 个月随访分析。
Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9.
7
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA).一项评估阿昔替尼新辅助治疗用于减少伴静脉侵犯的透明细胞肾细胞癌中静脉瘤栓程度的 II 期研究（NAXIVA）。
Br J Cancer. 2022 Oct;127(6):1051-1060. doi: 10.1038/s41416-022-01883-7. Epub 2022 Jun 23.
8
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy.新辅助纳武利尤单抗治疗接受肾切除术的局部晚期透明细胞肾细胞癌患者的 II 期研究。
Eur Urol. 2022 Jun;81(6):570-573. doi: 10.1016/j.eururo.2022.01.043. Epub 2022 Feb 17.
9
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.RAMPART：一项 III 期多臂多阶段试验，研究辅助检查点抑制剂在高或中复发风险的肾细胞癌（RCC）患者中的应用。
Contemp Clin Trials. 2021 Sep;108:106482. doi: 10.1016/j.cct.2021.106482. Epub 2021 Sep 16.
10
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.肾细胞癌肾切除术后辅助帕博利珠单抗。
N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391.
Zotero 插件